Bone tissue-engineered implants using human bone marrow stromal cells: Effect of culture conditions and donor age
Bone tissue-engineered implants using human bone marrow stromal cells: Effect of culture conditions and donor age
复制标题
DOI：
10.1089/107632702320934010
复制
发表时间：
2002-12-01
影响因子：
--
通讯作者：
Van Blitterswijk, CA
中科院分区：
文献类型：
--
作者：
Mendes, SC;Tibbe, JM;Van Blitterswijk, CA
目前，人类骨髓基质细胞（HBMSCs）群体可以分化成成骨细胞并产生骨，这是众所周知的。然而，最终获得的具有成骨潜能的细胞数量仍将取决于患者的生理状态和培养系统。此外，为了在骨科中使用细胞治疗方法，需要大量的细胞，因此需要了解影响这些细胞生长动力学的因素。在本研究中，我们研究了地塞米松刺激对造血干细胞体内成骨潜能的影响。经过增殖步骤后，将细胞在多孔磷酸钙支架上播种培养1周，然后裸鼠皮下植入6周，以评估其体内成骨能力。此外，我们还研究了供体年龄对培养物增殖率和诱导骨形成能力的影响。在67%的被测患者（12人中有8人）中，培养物中地塞米松的存在不需要获得体内骨组织形成。然而，在没有成骨能力或成骨程度低的培养物中，地塞米松增加了细胞的成骨能力。在细胞增殖过程中，与年轻供者相比，50岁以上供者的细胞生长速率明显与年龄相关。关于供体年龄对体内骨形成的影响，来自所有年龄组的几个供体的HBMSCs被证明具有体内成骨潜能，这表明细胞治疗在骨缺损修复中的应用可以不受患者年龄的影响。然而，供体年龄的增加显著降低了观察到骨形成的病例的频率。
At present, it is well known that populations of human bone marrow stromal cells (HBMSCs) can differentiate into osteoblasts and produce bone. However, the amount of cells with osteogenic potential that is ultimately obtained will still be dependent on both patient physiological status and culture system. In addition, to use a cell therapy approach in orthopedics, large cell numbers will be required and, as a result, knowledge of the factors affecting the growth kinetics of these cells is needed. In the present study we investigated the effect of dexamethasone stimulation on the in vivo osteogenic potential of HBMSCs. After a proliferation step, the cells were seeded and cultured on porous calcium phosphate scaffolds for 1 week, and then subcutaneously implanted in nude mice for 6 weeks, in order to evaluate their in vivo bone-forming ability. Furthermore, the effect of donor age on the proliferation rate of the cultures and their ability to induce in vivo bone formation was studied. In 67% of the assayed patients (8 of 12), the presence of dexamethasone in culture was not required to obtain in vivo bone tissue formation. However, in cultures without bone-forming ability or with a low degree of osteogenesis, dexamethasone increased the bone-forming capacity of the cells. During cellular proliferation, a significant age-related decrease was observed in the growth rate of cells from donors older than 50 years as compared with younger donors. With regard to the effect of donor age on in vivo bone formation, HBMSCs from several donors in all age groups proved to possess in vivo osteogenic potential, indicating that the use of cell therapy in the repair of bone defects can be applicable irrespective of patient age. However, the increase in donor age significantly decreased the frequency of cases in which bone formation was observed.